Published: 1 May 2019
Author(s): Roy Beigel, Israel Mazin, Orly Goitein, Romana Herscovici, Sharon Natanzon, Fernando Chernomordik, Sagit Ben-Zekry, Paul Fefer, Avishay Grupper, Shlomi Matetzky
Issue: May 2019
Section: Original Article

Intermediate-risk pulmonary embolism (PE) patients present a therapeutic dilemma. While some are at risk for developing adverse events, possibly requiring escalation therapy, most will have a benign course. Our aim was to define predictors which will identify those patients who will not deteriorate despite the presence of RV involvement.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.